INNOVATIL-04 CERVICAL CARCINOMA

Welcome to the Brand page for “INNOVATIL-04 CERVICAL CARCINOMA”, which is offered here for The mark consists of the term innovatil-04 and a design, with innova in green lower case letters and til in uppercase bold green letters and -04 in blue, and the design comprised of green and blue bars and dots in seven lines; and with the wording cervical carcinoma in all uppercase grey letters just below the innovatil-04 term.;innovatil-zero four cervical carcinoma;the color(s) green, blue and grey is/are claimed as a feature of the mark.;cervical carcinoma;conducting clinical trials for others for research and the treatment of cancer and oncological diseases; providing medical and scientific research information related to clinical trials for the treatment of cancer and oncological diseases; medical evaluation services, providing drug therapies and treatment programs for the treatment of cancer and oncological diseases, and providing assessments of treatment programs;.

Its status is currently believed to be active. Its class is unavailable. “INNOVATIL-04 CERVICAL CARCINOMA” is believed to be currently owned by “IOVANCE BIOTHERAPEUTICS, INC.”


Owner:
IOVANCE BIOTHERAPEUTICS, INC.
Owner Details
Description:
The mark consists of the term INNOVATIL-04 and a design, with innova in green lower case letters and TIL in uppercase bold green letters and -04 in blue, and the design comprised of green and blue bars and dots in seven lines; and with the wording CERVICAL CARCINOMA in all uppercase grey letters just below the INNOVATIL-04 term.;INNOVATIL-ZERO FOUR CERVICAL CARCINOMA;The color(s) green, blue and grey is/are claimed as a feature of the mark.;CERVICAL CARCINOMA;conducting clinical trials for others for research and the treatment of cancer and oncological diseases; providing medical and scientific research information related to clinical trials for the treatment of cancer and oncological diseases; medical evaluation services, providing drug therapies and treatment programs for the treatment of cancer and oncological diseases, and providing assessments of treatment programs;
Categories: